In the US, Ho PA et al., on behalf of the Children’s Oncology Group, screened 842 AML patients with diagnostic bone marrow specimens treated in three consecutive pediatric AML trials for WT1 mutations. The gene discussed is WT1; the disease is acute myeloid leukemia.